-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 E866WtO+VjbTOdYVdNtLUxSbs28oosGy6ATkIZ+2/dg/IPqhF5iQTbdFD0LLklJY
 Hh/OdY6+B97f2wSIEbMFkg==

<SEC-DOCUMENT>0000842023-08-000010.txt : 20080429
<SEC-HEADER>0000842023-08-000010.hdr.sgml : 20080429
<ACCEPTANCE-DATETIME>20080429092922
ACCESSION NUMBER:		0000842023-08-000010
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20080429
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20080429
DATE AS OF CHANGE:		20080429

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TECHNE CORP /MN/
		CENTRAL INDEX KEY:			0000842023
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				411427402
		STATE OF INCORPORATION:			MN
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-17272
		FILM NUMBER:		08783247

	BUSINESS ADDRESS:	
		STREET 1:		614 MCKINLEY PL N E
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55413
		BUSINESS PHONE:		6123798854

	MAIL ADDRESS:	
		STREET 1:		614 MCKINLEY PLACE NE
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55413
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>k8q.txt
<DESCRIPTION>8-K
<TEXT>
                      SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C. 20549

                                FORM 8-K

                              CURRENT REPORT

                  PURSUANT TO SECTION 13 OR 15(d) OF THE
                     SECURITIES EXCHANGE ACT OF 1934

    Date of report (Date of earliest event reported): April 29, 2008

                            TECHNE CORPORATION
             (Exact Name of Registrant as Specified in Charter)


       Minnesota                     0-17272             41-1427402
(State or Other Jurisdiction       (Commission         I.R.S. Employer
of Incorporation)                  File Number)      Identification No.)

                614 Mckinley Place NE
                   Minneapolis, MN                       55413
       (Address of Principal Executive Offices)       (Zip Code)

     Registrant's telephone number, including area code:  (612) 379-8854

                              Not Applicable
      (Former Name or Former Address, if changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any
of the following provisions:

/ /   Written communications pursuant to Rule 425 under the Securities Act
      17 CFR 230.425)

/ /   Soliciting material pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)

/ /   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

/ /   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))


<PAGE>



Item 2.02  Results of Operations and Financial Condition

A copy of the press release issued by Techne Corporation on April 29,
2008, describing the results of operations for the quarter and nine months
ended March 31, 2008 and its financial condition as of March 31, 2008,
is attached hereto as Exhibit 99.1.

Segment information for Techne Corporation for the quarter and nine months
ended March 31, 2008 which has been included on Techne Corporation's
website (www.techne-corp.com), is attached hereto as Exhibit 99.2.

The information in this Form 8-K and the Exhibits attached hereto shall not
be deemed "filed" for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the "Exchange Act"), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference
in any filing under the Securities Act of 1933 or the Exchange Act, except as
expressly set forth by specific reference in such filing.


Item 9.01 Financial Statements and Exhibits

     (d) Exhibits

         99.1 Press Release dated April 29, 2008.

         99.2 Segment information for the quarter and nine months ended
              March 31, 2008.






                            SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


Dated: April 29, 2008                TECHNE CORPORATION
                                      By: /s/ Thomas E. Oland
                                      ---------------------------
                                      Name: Thomas E. Oland
                                      Title: President and Chief
                                        Executive Officer



                          EXHIBIT INDEX

    Exhibit No. Description
    ----------- -----------
       99.1     Press release of Techne Corporation dated March 31, 2008.

       99.2     Segment information for Techne Corporation for the quarter
                and nine months ended March 31, 2008.

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>release42908.txt
<DESCRIPTION>PRESS RELEASE DATED 4/29/08
<TEXT>


                              TECHNE CORPORATION
                     RELEASES UNAUDITED THIRD QUARTER RESULTS
                             FOR FISCAL YEAR 2008

Minneapolis/April 29, 2008/--Techne Corporation's (NASDAQ: TECH) consolidated
net earnings for the quarter ended March 31, 2008 increased 23.8% to $29.6
million or $.76 per diluted share compared with $23.9 million or $.60 per
diluted share for the quarter ended March 31, 2007.  For the nine months
ended March 31, 2008, Techne's consolidated net earnings increased 22.7% to
$76.3 million or $1.94 per diluted share compared with $62.2 million or $1.57
per diluted share for the nine months ended March 31, 2007.

Net earnings as a percentage of net sales improved to 40.2% for the nine
months ended March 31, 2008 from 37.7% in the first nine months of last year.
The improvement in net earnings was mainly due to increased consolidated net
sales. The favorable impact on consolidated net earnings of the change in
exchange rates used to convert foreign currencies (primarily British pound
sterling and Euros) to U.S. dollars was $251,000 ($.006 per diluted share)
for the quarter and $1.0 million ($.026 per diluted share) for the nine
months ended March 31, 2008.

Consolidated net sales for the quarter and nine months ended March 31, 2008
were $69.5 million and $189.7 million, respectively. This was an increase of
15.5% and 14.9% from the quarter and nine months ended March 31, 2007,
respectively. Consolidated net sales were favorably affected by the strength
of foreign currencies as compared to the U.S. dollar. Excluding the effect of
changes in foreign currency exchange rates, consolidated net sales increased
12.6% and 12.4% for the quarter ended and nine months ended March 31, 2008,
respectively, from the comparable prior year periods.

Biotechnology net sales, which include sales by R&D Systems' Biotechnology
Division, R&D Systems China and BiosPacific, were $45.1 million and $123.1
million, for the quarter and nine months ended March 31, 2008, increases of
15.2% and 13.5%, respectively.  This improvement was primarily the result of
increased volume, including shipments to diagnostic customers.  The timing of
diagnostic customer sales is not predictable and these sales increases are
not necessarily indicative of future sales.  Excluding the increased sales to
diagnostic customers, Biotechnology net sales increased 13.2% and 12.6% for
the quarter ended and nine months ended March 31, 2008, respectively, from
the comparable prior year periods.

R&D Europe's net sales for the quarter and nine months ended March 31, 2008
were $20.2 million and $54.7 million, increases of 16.2% and 20.0%,
respectively, from the same prior-year periods.  R&D Europe's net sales
increased 6.0% and 10.9% for the quarter and nine months ended March 31, 2008
when measured at currency rates in effect in the comparable prior periods.
Hematology net sales for the quarter and nine months ended March 31, 2008
were $4.2 million and $11.8 million, increases of 14.8% and 7.7%,
respectively, compared to the quarter and nine months ended March 31, 2007.
The timing of shipments to OEM customers positively impacted Hematology sales
results during the quarter ended March 31, 2008.

Tom Oland, President and Chief Executive Officer of Techne Corporation, said
"Sales exceeded our expectations in all segments of our business and in
nearly all product lines and geographical territories for the second straight
quarter. The Easter holiday had much less impact on sales than we anticipated
and we benefited from a large one-time $1.1 million sale to a diagnostic
customer."

Mr. Oland added, "While improvement in recent market demand has allowed the
Company to capitalize on its expanding product line and commitment to
quality, we continue to believe that, given current market conditions, our
long-term sales growth will be in a targeted range of 8% to 10%, excluding
the effect of changes in exchange rates."

Consolidated gross margins were 79.7% and 79.4% for the quarter and nine
months ended March 31, 2008, respectively, compared to 80.0% and 79.4% for
the quarter and nine months ended March 31, 2007, respectively. Biotechnology
gross margins decreased to 79.8% for both the quarter and nine months ended
March 31, 2008 from 80.4% and 80.3% for the same prior-year periods mainly as
a result of higher volume sales to diagnostic customers. The decrease in
Biotechnology gross margins was partially offset by higher margins in Europe
due to favorable exchange rates and changes in sales mix as a result of
higher sales growth in the Biotechnology Division as compared to the sales
growth in the lower margin Hematology Division.

Selling, general and administrative expenses for the quarter and nine months
ended March 31, 2008 increased $1.8 million (24.4%) and $4.6 million (19.9%),
respectively. These increases include wage and salary increases and the
hiring of additional marketing and administrative personnel to support the
Company's sales growth. The third quarter increase also resulted from
increased legal fees of $559,000, additional profit sharing of $620,000,
increased bad debt expense of $124,000, R&D China selling, and general and
administrative expenses of $149,000.

Selling, general and administrative expenses for the nine months ended March
31, 2008 also increased because of additional profit sharing of $1.2 million,
increased legal fees of $930,000, R&D China selling, general and
administrative expenses of $392,000, the change in foreign currency exchange
rates used to convert British pounds to U.S. dollars of $310,000, increased
stock option expense of $196,000, and increased bad debt expense of $124,000.

The effective tax rates for the quarter and nine months ended March 31, 2008
were 31.2% and 32.7%, respectively, as compared to effective tax rates of
35.2% and 34.4%, respectively, from the same prior-year periods. Third
quarter rates in both fiscal years were impacted by changes in state
apportionment estimates.  Without significant business developments, the
Company expects its fiscal 2008 effective income tax rate to range from
approximately 33.0% to 34.0%.

The Company repurchased approximately 437,000 shares of its common stock
during the third quarter of fiscal 2008 for approximately $28.7 million.
During fiscal 2008 and through March 31, 2008, the Company has repurchased
approximately 758,000 shares of its common stock for approximately $49.3
million.

Forward Looking Statements:

This earnings release contains forward-looking statements within the meaning
of the Private Litigation Reform Act.  These statements, including the
Company's expectations as to growth rates and income tax rates, involve risks
and uncertainties that may affect the actual results of operations. The
following important factors, among others, have affected and, in the future,
could affect the Company's actual results: the introduction and acceptance of
new biotechnology and hematology products, the levels and particular
directions of research by the Company's customers, the impact of the growing
number of producers of biotechnology research products and related price
competition, the retention of hematology OEM and proficiency survey business,
the impact of currency exchange rate fluctuations, and the costs and results
of research and product development efforts of the Company and of companies
in which the Company has invested or with which it has formed strategic
relationships.

For additional information concerning such factors, see the Company's annual
report on Form 10-K and quarterly reports on Form 10-Q as filed with the
Securities and Exchange Commission.  We undertake no obligation to update or
revise any forward-looking statements we make in this release due to new
information or future events.  Investors are cautioned not to place undue
emphasis on these statements.

                  *  *  *  *  *  *  *  *  *  *  *  *  *

Techne Corporation has two operating subsidiaries:  Research and Diagnostic
Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe,
Ltd. (R&D Europe) of Abingdon, England.  R&D Systems is a specialty
manufacturer of biological products.  R&D Systems has two subsidiaries,
BiosPacific, Inc. (BiosPacific), located in Emeryville, California and R&D
Systems China Co. Ltd., (R&D China), located in Shanghai, China.  BiosPacific
is a worldwide supplier of biologics to manufacturers of in vitro diagnostic
systems and immunodiagnostic kits. R&D China and R&D Europe distribute
biotechnology products.

Contact:  Greg Melsen, Chief Financial Officer
          Kathy Backes, Controller
          (612) 379-8854


                         TECHNE CORPORATION
               CONSOLIDATED STATEMENTS OF EARNINGS
               (In thousands, except per share data)
                            (Unaudited)
                                         QUARTER ENDED     NINE MONTHS ENDED
                                        ----------------  ------------------
                                        3/31/08  3/31/07   3/31/08   3/31/07
                                        -------  -------  --------  --------
Net sales                               $69,522  $60,197  $189,651  $165,057
Cost of sales                            14,146   12,019    39,001    33,970
                                        -------  -------  --------  --------
Gross margin                             55,376   48,178   150,650   131,087
                                        -------  -------  --------  --------

Operating expenses:
 Selling, general and administrative      8,994    7,229    27,729    23,126
 Research and development                 5,839    5,169    16,582    15,068
 Amortization of intangible assets          283      403       853     1,210
                                        -------  -------  --------  --------
      Total operating expenses           15,116   12,801    45,164    39,404
                                        -------  -------  --------  --------
Operating income                         40,260   35,377   105,486    91,683
                                        -------  -------  --------  --------
Other expense (income):
 Interest expense                            --       --        --     1,083
 Interest income                         (3,155)  (2,237)   (9,405)   (5,869)
 Other non-operating expense, net           423      767     1,565     1,680
                                        -------  -------  --------  --------
       Total other income                (2,732)  (1,470)   (7,840)   (3,106)
                                        -------  -------  --------  --------
Earnings before income taxes             42,992   36,847   113,326    94,789
Income taxes                             13,402   12,954    37,025    32,602
                                        -------  -------  --------  --------
Net earnings                            $29,590  $23,893  $ 76,301  $ 62,187
                                        =======  =======  ========  ========
Earnings per share:
 Basic                                  $  0.76  $  0.61  $   1.94  $   1.58
 Diluted                                $  0.76  $  0.60  $   1.94  $   1.57

Weighted average common
 shares outstanding:
 Basic                                   39,000   39,414    39,296    39,393
 Diluted                                 39,108   39,543    39,396    39,498



                          TECHNE CORPORATION
                     CONSOLIDATED BALANCE SHEETS
                           (In thousands)
                             (Unaudited)

                                               3/31/08   6/30/07
                                              --------  --------
ASSETS:
Cash and equivalents                          $162,849  $135,485
Short-term available-for-sale investments       42,947    29,289
Trade accounts receivable                       32,798    29,559
Other receivables                                1,407     1,407
Inventory                                       10,003     8,757
Other current assets                             9,357     8,341
                                              --------  --------
  Current assets                               259,361   212,838
                                              --------  --------

Available-for-sale investments                  75,097    91,433
Property and equipment, net                     94,069    91,535
Goodwill and intangible assets, net             29,314    30,167
Other non-current assets                        30,269    28,871
                                              --------  --------
  Total assets                                $488,110  $454,844
                                              ========  ========
LIABILITIES
Current liabilities                           $ 20,162  $ 17,193
Stockholders' equity                           467,948   437,651
                                              --------  --------
  Total liabilities and equity                $488,110  $454,844
                                              ========  ========

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>seg308.txt
<DESCRIPTION>SEGMENT RESULTS
<TEXT>
                              SEGMENT INFORMATION

                     TECHNE CORPORATION AND SUBISIDARIES
                  (in thousands of $'s, except per share data)

<TABLE>
<CAPTION>
                                                                       Increase (Decrease)
                                       Fiscal 2008                      From Fiscal 2007
                       ----------------------------------------  ------------------------------
                        First  Second   Third           Percent  First  Second   Third
                        Qtr     Qtr     Qtr     YTD    Of Sales   Qtr     Qtr    Qtr      YTD
                       ------  ------  ------  ------- --------  ------  ------  ------  ------
<S>                   <C>     <C>     <C>     <C>       <C>      <C>     <C>    <C>     <C>
Sales                  57,987  62,142  69,522  189,651   100%     5,636   9,633   9,325  24,594
Cost of sales          12,104  12,751  14,146   39,001    21%       867   2,037   2,127   5,031
                       ------  ------  ------  ------- --------  ------  ------  ------  ------
Gross margin           45,883  49,391  55,376  150,650    79%     4,769   7,596   7,198  19,563

Gross margin
 percentage              79.1%   79.5%   79.7%    79.4%

SG&A expense            8,090  10,645   8,994   27,729    15%     1,023   1,815   1,765   4,603
R&D expense             5,181   5,562   5,839   16,582     9%       326     518     670   1,514
Amortization expense      288     282     283      853     -       (115)   (122)   (120)   (357)
Interest expense            0       0       0        0     -       (268)   (815)      0  (1,083)
Interest income        (2,998) (3,252) (3,155)  (9,405)   (5%)   (1,322) (1,296)   (918) (3,536)
Other non-operating
  expense, net            569     573     423    1,565     -         84     145    (344)   (115)
                       ------  ------  ------  ------- --------  ------  ------  ------  ------
                       11,130  13,810  12,384   37,324    19%      (272)    245   1,053   1,026
                       ------  ------  ------  ------- --------  ------  ------  ------  ------
Earnings before
 income taxes          34,753  35,581  42,992  113,326    60%     5,041   7,351   6,145  18,537
Income taxes           11,681  11,942  13,402   37,025    20%     1,600   2,375     448   4,423
                       ------  ------  ------  ------- --------  ------  ------  ------  ------
                       23,072  23,639  29,590   76,301    40%     3,441   4,976   5,697  14,114
                       ======  ======  ======  ======= ========  ======  ======  ======  ======
Diluted earnings
 per share                .58     .60     .76     1.94
Weighted average
 diluted shares
 outstanding           39,587  39,497  39,108  39,396

</TABLE>


                                     BIOTECHNOLOGY  (1)
                                    (in thousands of $'s)
<TABLE>
<CAPTION>
                                                                       Increase (Decrease)
                                       Fiscal 2008                      From Fiscal 2007
                       ----------------------------------------  ------------------------------
                        First  Second   Third           Percent  First  Second   Third
                        Qtr     Qtr     Qtr     YTD    Of Sales   Qtr     Qtr    Qtr      YTD
                       ------  ------  ------  ------- --------  ------  ------  ------  ------
<S>                   <C>     <C>     <C>     <C>       <C>      <C>     <C>    <C>     <C>
Sales                  45,328  46,576  52,912  144,816   100%     3,707   6,503   6,710  16,920
Intersegment sales     (6,447) (7,433) (7,822) (21,702)            (748)   (786)   (750) (2,284)
                       ------  ------  ------  -------           ------  ------  ------  ------
                       38,881  39,143  45,090  123,114            2,959   5,717   5,960  14,636

Cost of sales           8,997   9,612  10,709   29,318    20%       515   1,929   1,668   4,112
Intersegment sales     (6,174) (7,430) (7,755) (21,359)            (650)   (995)   (608) (2,253)
                       ------  ------  ------  -------           ------  ------  ------  ------
                        2,823   2,182   2,954    7,959             (135)    934   1,060   1,859

Gross margin           36,058  36,961  42,136  115,155    80%     3,094   4,783   4,900  12,777

Gross margin
 percentage              80.2%   79.4%   79.8%    79.8%

SG&A expense            4,624   5,534   5,257   15,415    11%       611     870   1,091   2,572
R&D expense             5,002   5,368   5,640   16,010    11%       327     514     669   1,510
Amortization expense      288     282     283      853     1%      (115)   (122)   (120)   (357)
Interest, net          (1,257) (1,309) (1,285)  (3,851)   (3%)     (662)   (587)   (444) (1,693)
Exchange loss/(gain)       34      12      (5)      41    --         34      12      (5)     41
                       ------  ------  ------  ------- --------  ------  ------  ------  ------
                        8,691   9,887   9,890   28,468    20%       195     687   1,191   2,073
                       ------  ------  ------  ------- --------  ------  ------  ------  ------
Pretax result          27,367  27,074  32,246   86,687    60%     2,899   4,096   3,709  10,704
                       ======  ======  ======  ======= ========  ======  ======  ======  ======
</TABLE>

(1)	Includes R&D Systems' Biotechnology Division,
     BiosPacific, Inc. and R&D China


                                    R&D SYSTEMS EUROPE
                             (in thousands of British pounds)
<TABLE>
<CAPTION>
                                                                       Increase (Decrease)
                                       Fiscal 2008                      From Fiscal 2007
                       ----------------------------------------  ------------------------------
                        First  Second   Third           Percent  First  Second   Third
                        Qtr     Qtr     Qtr     YTD    Of Sales   Qtr     Qtr    Qtr      YTD
                       ------  ------  ------  ------- --------  ------  ------  ------  ------
<S>                   <C>     <C>     <C>     <C>       <C>      <C>     <C>    <C>     <C>
Sales                   7,605   9,301  10,180   27,086    100%      735   1,450   1,326   3,511
Cost of sales           3,455   4,053   4,392   11,900     44%      170     287     301     758
                       ------  ------  ------  ------- --------  ------  ------  ------  ------
Gross margin            4,150   5,248   5,788   15,186     56%      565   1,163   1,025   2,753

Gross margin
 percentage              54.6%   56.4%   56.9%    56.1%

SG&A expense            1,114   1,276   1,163    3,553     13%       40      40      88     168
Interest income          (683)   (773)   (762)  (2,218)    (8%)    (273)   (293)   (220)   (786)
Exchange loss/(gain)      (96)    (81)   (230)    (407)    (2%)    (174)    (17)   (252)   (443)
                       ------  ------  ------  ------- --------  ------  ------  ------  ------
                          335     422     171      928      3%     (407)   (270)   (384) (1,061)
                       ------  ------  ------  ------- --------  ------  ------  ------  ------
Pretax result           3,815   4,826   5,617   14,258     53%      972   1,433   1,409   3,814
                       ======  ======  ======  ======= ========  ======  ======  ======  ======

</TABLE>


                                   R&D SYSTEMS EUROPE
                                   (in thousands of $'s)
<TABLE>
<CAPTION>
                                                                       Increase (Decrease)
                                       Fiscal 2008                      From Fiscal 2007
                       ----------------------------------------  ------------------------------
                        First  Second   Third           Percent  First  Second   Third
                        Qtr     Qtr     Qtr     YTD    Of Sales   Qtr     Qtr    Qtr      YTD
                       ------  ------  ------  ------- --------  ------  ------  ------  ------
<S>                   <C>     <C>     <C>     <C>       <C>      <C>     <C>    <C>     <C>
Sales                  15,449  19,027  20,226   54,702    100%    2,522   3,770   2,823   9,115
Cost of sales           7,020   8,293   8,726   24,039     44%      839     974     686   2,499
                       ------  ------  ------  ------- --------  ------  ------  ------  ------
Gross margin            8,429  10,734  11,500   30,663     56%    1,683   2,796   2,137   6,616

Gross margin
 percentage              54.6%   56.4%   56.9%    56.1%

SG&A expense            2,262   2,599   2,311    7,172     13%      242     194     199     635
Interest income        (1,387) (1,576) (1,514)  (4,477)    (8%)    (616)   (643)   (447) (1,706)
Exchange loss/gain)      (198)   (165)   (457)    (820)    (2%)    (345)    (39)   (499)   (883)
                       ------  ------  ------  ------- --------  ------  ------  ------  ------
                          677     858     340    1,875      3%     (719)   (488)   (747) (1,954)
                       ------  ------  ------  ------- --------  ------  ------  ------  ------
Pretax result           7,752   9,876  11,160   28,788     53%    2,402   3,284   2,884   8,570
                       ======  ======  ======  ======= ========  ======  ======  ======  ======

</TABLE>


                                        HEMATOLOGY
                                   (in thousands of $'s)
<TABLE>
<CAPTION>
                                                                       Increase (Decrease)
                                       Fiscal 2008                      From Fiscal 2007
                       ----------------------------------------  ------------------------------
                        First  Second   Third           Percent  First  Second   Third
                        Qtr     Qtr     Qtr     YTD    Of Sales   Qtr     Qtr    Qtr      YTD
                       ------  ------  ------  ------- --------  ------  ------  ------  ------
<S>                   <C>     <C>     <C>     <C>       <C>      <C>     <C>    <C>     <C>
Sales                   3,657   3,972   4,206   11,835    100%      155     146     542     843
Cost of sales           2,261   2,276   2,466    7,003     59%      163     129     381     673
                       ------  ------  ------  ------- --------  ------  ------  ------  ------
Gross margin            1,396   1,696   1,740    4,832     41%       (8)     17     161     170

Gross margin
 percentage              38.2%   42.7%   41.4%    40.8%

SG&A expense              467     487     489    1,443     12%       69      48      58     175
R&D expense               179     194     199      572      5%       (1)      4       1       4
Interest, net            (120)   (125)   (123)    (368)    (3%)     (39)    (30)    (12)    (81)
                       ------  ------  ------  ------- --------  ------  ------  ------  ------
                          526     556     565    1,647     14%       29      22      47      98
                       ------  ------  ------  ------- --------  ------  ------  ------  ------
Pretax result             870   1,140   1,175    3,185     27%      (37)     (5)    114      72
                       ======  ======  ======  ======= ========  ======  ======  ======  ======

</TABLE>



                                CORPORATE AND OTHER (2)
                                  (in thousands of $'s)
<TABLE>
<CAPTION>
                                                               Increase (Decrease)
                                         Fiscal 2008              From Fiscal 2007
                         -------------------------------  ------------------------------
                          First  Second   Third            First  Second   Third
                          Qtr     Qtr     Qtr     YTD       Qtr     Qtr    Qtr      YTD
                         ------  ------  ------  -------  ------  ------  ------  ------
<S>                     <C>     <C>     <C>     <C>       <C>     <C>    <C>     <C>
Interest income             234     242     233      709       5      36      15      56
Rental income                67     111      91      269    (232)   (130)     36    (326)
                         ------  ------  ------  -------  ------  ------  ------  ------
                            301     353     324      978    (227)    (94)     51    (270)

SG&A expense                737   2,025     937    3,699     101     703     417   1,221
Interest expense             --      --      --       --    (268)   (815)     --  (1,083)
Other-Building expenses     544     600     633    1,777      34      51     114     199
Other-Equity Investment
 losses                     256     237     343      836     129      (9)     82     202
                         ------  ------  ------  -------  ------  ------  ------  ------
                          1,537   2,862   1,913    6,312      (4)    (70)    613     539
                         ------  ------  ------  -------  ------  ------  ------  ------
Pretax result            (1,236) (2,509) (1,589)  (5,334)   (223)    (24)   (562)   (809)
                         ======  ======  ======  =======  ======  ======  ======  ======
</TABLE>


(2)	Unallocated corporate expenses and Techne's
      share of losses by Hemerus Medical, LLC and Nephromics, LLC.
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
